| 1TXI | A: | CRYSTAL STRUCTURE OF THE VDR LIGAND BINDING DOMAIN COMPLEXED TO TX522 |
| 1XJ7 | A: | COMPLEX ANDROGEN RECEPTOR LBD AND RAC3 PEPTIDE |
| 1XQC | A:; B:; C:; D: | X-RAY STRUCTURE OF ERALPHA LBD BOUND TO A TETRAHYDROISOQUINOLINE SERM LIGAND AT 2.05A RESOLUTION |
| 1Y9R | A:; B: | CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION |
| 1YA3 | A:; B:; C: | CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO PROGESTERONE AND HARBORING THE S810L MUTATION RESPONSIBLE FOR A SEVERE FORM OF HYPERTENSION |
| 1YOK | A: | CRYSTAL STRUCTURE OF HUMAN LRH-1 BOUND WITH TIF-2 PEPTIDE AND PHOSPHATIDYLGLYCEROL |
| 1YUC | A:; B: | HUMAN NUCLEAR RECEPTOR LIVER RECEPTOR HOMOLOGUE-1, LRH-1, BOUND TO PHOSPHOLIPID AND A FRAGMENT OF HUMAN SHP |
| 1Z95 | A: | CRYSTAL STRUCTURE OF THE ANDROGEN RECEPTOR LIGAND-BINDING DOMAIN W741L MUTANT COMPLEX WITH R-BICALUTAMIDE |
| 1ZDU | A: | THE CRYSTAL STRUCTURE OF HUMAN LIVER RECEPTOR HOMOLOGUE-1 |
| 1ZGY | A: | STRUCTURAL AND BIOCHEMICAL BASIS FOR SELECTIVE REPRESSION OF THE ORPHAN NUCLEAR RECEPTOR LRH-1 BY SHP |
| 2A3I | A: | STRUCTURAL AND BIOCHEMICAL MECHANISMS FOR THE SPECIFICITY OF HORMONE BINDING AND COACTIVATOR ASSEMBLY BY MINERALOCORTICOID RECEPTOR |
| 2AA2 | A: | MINERALOCORTICOID RECEPTOR WITH BOUND ALDOSTERONE |
| 2AA5 | A:; B: | MINERALOCORTICOID RECEPTOR WITH BOUND PROGESTERONE |
| 2AA6 | A:; B: | MINERALOCORTICOID RECEPTOR S810L MUTANT WITH BOUND PROGESTERONE |
| 2AA7 | A: | MINERALOCORTICOID RECEPTOR WITH BOUND DEOXYCORTICOSTERONE |
| 2AAX | A:; B: | MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND CORTISONE |
| 2AB2 | A:; B: | MINERALOCORTICOID RECEPTOR DOUBLE MUTANT WITH BOUND SPIRONOLACTONE |
| 2ABI | A:; B:; C: | CRYSTAL STRUCTURE OF THE HUMAN MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN BOUND TO DEOXYCORTICOSTERONE |
| 2ATH | A:; B: | CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IM COMPLEX WITH AN AGONIST |
| 2BAW | A:; B: | HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1 |
| 2E2R | A: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL A |
| 2F4B | A:; B: | CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH AN AGONIST |
| 2FVJ | A: | A NOVEL ANTI-ADIPOGENIC PARTIAL AGONIST OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA (PPARG) RECRUITS PPARG-COACTIVATOR-1 ALPHA (PGC1A) BUT POTENTIATES INSULIN SIGNALING IN VITRO |
| 2GL8 | A:; B:; C:; D: | HUMAN RETINOIC ACID RECEPTOR RXR-GAMMA LIGAND-BINDING DOMAIN |
| 2H77 | A: | CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN MONOCLINIC SPACE GROUP |
| 2H79 | A: | CRYSTAL STRUCTURE OF HUMAN TR ALPHA BOUND T3 IN ORTHORHOMBIC SPACE GROUP |
| 2HAM | A: | CRYSTAL STRUCTURE OF VDR LBD COMPLEXED TO 2ALPHA-PROPYL-CALCITRIOL |
| 2HAR | A: | CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2 ALPHA-(3-HYDROXY-1-PROPOXY) CALCITRIOL |
| 2HAS | A: | CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-(1-PROPOXY) CALCITRIOL |
| 2HB7 | A: | CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA(3-HYDROXY-1-PROPYL) CALCITRIOL |
| 2HB8 | A: | CRYSTAL STRUCTURE OF VDR LBD IN COMPLEX WITH 2ALPHA-METHYL CALCITRIOL |
| 2HWQ | A:; B: | STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS |
| 2HWR | A:; B: | STRUCTURAL BASIS FOR THE STRUCTURE-ACTIVITY RELATIONSHIPS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS |
| 2J14 | A:; B: | 3,4,5-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2 |
| 2J4A | A: | HUMAN THYROID HORMONE RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH KB131084 |
| 2JFA | A:; B: | ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH AN AFFINITY-SELECTED COREPRESSOR PEPTIDE |
| 2JJ3 | A:; B: | ESTROGEN RECEPTOR BETA LIGAND BINDING DOMAIN IN COMPLEX WITH A BENZOPYRAN AGONIST |
| 2OAX | A:; B:; C:; D:; E:; F: | CRYSTAL STRUCTURE OF THE S810L MUTANT MINERALOCORTICOID RECEPTOR ASSOCIATED WITH SC9420 |
| 2OM9 | A:; B:; C:; D: | AJULEMIC ACID, A SYNTHETIC CANNABINOID BOUND TO PPAR GAMMA |
| 2QMV | A: | HIGH RESOLUTION STRUCTURE OF PEROXISONE PROLIFERATION-ACTIVATED RECEPTOR GAMMA AND CHARACTERISATION OF ITS INTERACTION WITH THE CO-ACTIVATOR TRANSCRIPTIONAL INTERMEDIARY FACTOR 2 |
| 2VSR | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 9-(S)-HODE |
| 2VST | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 13-(S)-HODE |
| 2VV0 | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH DHA |
| 2VV1 | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-HDHA |
| 2VV2 | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 5-HEPA |
| 2VV3 | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 4-OXODHA |
| 2VV4 | A:; B: | HPPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 6-OXOOTE |
| 2W8Y | A:; B: | RU486 BOUND TO THE PROGESTERONE RECEPTOR IN A DESTABILIZED AGONISTIC CONFORMATION |
| 2XYJ | A:; B: | NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY |
| 2XYW | A:; B: | NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY |
| 2XYX | A:; B: | NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY |
| 2YAT | A: | CRYSTAL STRUCTURE OF ESTRADIOL DERIVED METAL CHELATE AND ESTROGEN RECEPTOR-LIGAND BINDING DOMAIN COMPLEX |
| 2YFE | A:; B: | LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 1 |
| 2YLO | A: | TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING |
| 2YLP | A: | TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING |
| 2YLQ | A: | TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING |
| 2ZAS | A: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH 4-ALPHA-CUMYLPHENOL, A BISPHENOL A DERIVATIVE |
| 2ZBS | A: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN APO FORM |
| 2ZKC | A:232-457 | CRYSTAL STRUCTURE OF HUMAN ESTROGEN-RELATED RECEPTOR GAMMA LIGAND BINDING DOMAIN COMPLEX WITH BISPHENOL Z |
| 3A3Z | X: | CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277A(C23S) |
| 3A40 | X: | CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND 2ALPHA-METHYL-AMCR277B(C23R) |
| 3A78 | A: | CRYSTAL STRUCTURE OF THE HUMAN VDR LIGAND BINDING DOMAIN BOUND TO THE NATURAL METABOLITE 1ALPHA,25-DIHYDROXY-3-EPI-VITAMIN D3 |
| 3ADS | A:; B: | HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN |
| 3ADT | A:; B: | HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-HYDROXY-INDOLE ACETATE |
| 3ADU | A:; B: | HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE |
| 3ADV | A:; B: | HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH SEROTONIN |
| 3ADW | A:; B: | HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH 5-METHOXY-INDOLE ACETATE AND 15-OXO-EICOSATETRAENOIC ACID |
| 3ADX | A:; B: | HUMAN PPARGAMMA LIGAND-BINDING DOMAIN IN COMPLEX WITH INDOMETHACIN AND NITRO-233 |
| 3AUQ | A: | CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2ALPHA-METHYL-19-NORVITAMIN D3 |
| 3AUR | A: | CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH YNE-DIENE TYPE ANALOG OF ACTIVE 14-EPI-2BETA-METHYL-19-NORVITAMIN D3 |
| 3BEJ | A:; B: | STRUCTURE OF HUMAN FXR IN COMPLEX WITH MFA-1 AND CO-ACTIVATOR PEPTIDE |
| 3CDP | A:; B: | CRYSTAL STRUCTURE OF PPAR-GAMMA LBD COMPLEXED WITH A PARTIAL AGONIST, ANALOGUE OF CLOFIBRIC ACID |
| 3CDS | A:; B: | CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN PPAR-GAMMA AND THE AGONIST LT248 (CLOFIBRIC ACID ANALOGUE) |
| 3CS8 | A: | STRUCTURAL AND BIOCHEMICAL BASIS FOR THE BINDING SELECTIVITY OF PPARG TO PGC-1A |
| 3CWD | A:; B: | MOLECULAR RECOGNITION OF NITRO-FATTY ACIDS BY PPAR GAMMA |
| 3D57 | A:; B: | TR VARIANT D355R |
| 3D5F | A:; B: | CRYSTAL STRUCTURE OF PPAR-DELTA COMPLEX |
| 3DCT | A: | FXR WITH SRC1 AND GW4064 |
| 3DCU | A: | FXR WITH SRC1 AND GSK8062 |
| 3FS1 | A: | CRYSTAL STRUCTURE OF HNF4A LBD IN COMPLEX WITH THE LIGAND AND THE COACTIVATOR PGC-1A FRAGMENT |
| 3FUR | A: | CRYSTAL STRUCTURE OF PPARG IN COMPLEX WITH INT131 |
| 3FXV | A: | IDENTIFICATION OF AN N-OXIDE PYRIDINE GW4064 ANALOGUE AS A POTENT FXR AGONIST |
| 3G8O | A:; B: | PROGESTERONE RECEPTOR WITH BOUND PYRROLIDINE 1 |
| 3GBK | A:; B: | CRYSTAL STRUCTURE OF HUMAN PPAR-GAMMA LIGAND BINDING DOMAIN COMPLEXED WITH A POTENT AND SELECTIVE AGONIST |
| 3GN8 | A:; B: | X-RAY CRYSTAL STRUCTURE OF ANCGR2 IN COMPLEX WITH DEXAMETHASONE |
| 3H52 | A:; B:; C:; D: | CRYSTAL STRUCTURE OF THE ANTAGONIST FORM OF HUMAN GLUCOCORTICOID RECEPTOR |
| 3HLV | A:; B: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND 16-ALPHA-HYDROXY-ESTRONE ((8S,9R,13S,14R, 16R)-3,16-DIHYDROXY-13-METHYL-7,8,9,11,12,14,15, 16-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE |
| 3HM1 | A:; B: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTRONE ((8R,9S,13S,14S)-3-HYDROXY-13-METHYL-7,8,9,11,12,14,15,16-OCTAHYDRO-6H-CYCLOPENTA[A]PHENANTHREN-17-ONE) |
| 3HZF | A: | STRUCTURE OF TR-ALFA BOUND TO SELECTIVE THYROMIMETIC GC-1 IN C2 SPACE GROUP |
| 3K22 | A:; B: | GLUCOCORTICOID RECEPTOR WITH BOUND ALANINAMIDE 10 WITH TIF2 PEPTIDE |
| 3K23 | A:; B:; C: | GLUCOCORTICOID RECEPTOR WITH BOUND D-PROLINAMIDE 11 |
| 3K6P | A: | ESTROGEN RELATED RECEPTOR ALPHA IN COMPLEX WITH AN ETHER BASED LIGAND |
| 3KFC | A:; B:; C:; D: | COMPLEX STRUCTURE OF LXR WITH AN AGONIST |
| 3L03 | A:; B: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH A GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 NR BOX II PEPTIDE AND ESTETROL (ESTRA-1,3,5(10)-TRIENE-3,15 ALPHA, 16ALPHA,17BETA-TETROL) |
| 3L0E | A: | X-RAY CRYSTAL STRUCTURE OF A POTENT LIVER X RECEPTOR MODULATOR |
| 3OKH | A: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 2-(4-CHLOROPHENYL)-1-[(1S)-1-CYCLOHEXYL-2-(CYCLOHEXYLAMINO)-2-OXOETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID |
| 3OKI | A:; C: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4-CHLOROPHENYL)-1H-BENZIMIDAZOL-1-YL]-N,2-DICYCLOHEXYLETHANAMIDE |
| 3OLF | A:; C: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4-CHLOROPHENYL)-5,6-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYLACETYL}AMINO)-3-METHYLBENZOIC ACID |
| 3OMK | A:; C: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH (2S)-2-[2-(4-CHLOROPHENYL)-5,6-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYL-N-(2-METHYLPHENYL)ETHANAMIDE |
| 3OMM | A:; C: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4-CHLOROPHENYL)-5,6-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYLACETYL}AMINO)-3-FLUOROBENZOIC ACID |
| 3OOF | A:; C: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4-CHLOROPHENYL)-5,6-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYLACETYL}AMINO)BENZOIC ACID |
| 3OOK | A:; C: | CRYSTAL STRUCTURE OF HUMAN FXR IN COMPLEX WITH 4-({(2S)-2-[2-(4-CHLOROPHENYL)-5,6-DIFLUORO-1H-BENZIMIDAZOL-1-YL]-2-CYCLOHEXYLACETYL}AMINO)-3,5-DIFLUOROBENZOIC ACID |
| 3PLZ | A:; B: | HUMAN LRH1 LBD BOUND TO GR470 |
| 3Q95 | A:; B: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND ESTRIOL |
| 3Q97 | A:; B: | CRYSTAL STRUCTURE OF HUMAN ESTROGEN RECEPTOR ALPHA LBD IN COMPLEX WITH GRIP PEPTIDE AND TWO ISOMERS OF ETHOXY TRIPHENYLETHYLENE |
| 3VHU | A: | MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH SPIRONOLACTONE |
| 3VHV | A: | MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH NON-STEROIDAL ANTAGONIST |
| 3VHW | A: | CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 4-MP |
| 3WFF | A: | MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2B |
| 3WFG | A: | MINERALOCORTICOID RECEPTOR LIGAND-BINDING DOMAIN WITH COMPUOND 2E |
| 3ZR7 | A:; B: | STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS |
| 3ZRA | A:; B: | STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS |
| 3ZRB | A:; B: | STRUCTURAL BASIS FOR AGONISM AND ANTAGONISM FOR A SET OF CHEMICALLY RELATED PROGESTERONE RECEPTOR MODULATORS |
| 4A2J | A:; B: | PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROIDS |
| 4A4V | A:; B: | LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 |
| 4A4W | A:; B: | LIGAND BINDING DOMAIN OF HUMAN PPAR GAMMA IN COMPLEX WITH AMORFRUTIN 2 |
| 4APU | A:; B: | PR X-RAY STRUCTURES IN AGONIST CONFORMATIONS REVEAL TWO DIFFERENT MECHANISMS FOR PARTIAL AGONISM IN 11BETA-SUBSTITUTED STEROID |
| 4IS8 | A:; B: | DIVERGENT SEQUENCE TUNES LIGAND SENSITIVITY IN PHOSPHOLIPID-REGULATED HORMONE RECEPTORS |
| 4ITE | A: | CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA,25-DIHYDROXY-2ALPHA-[2-(2H-TETRAZOL-2-YL)ETHYL]VITAMIN D3 |
| 4ITF | A: | CRYSTAL STRUCTURE OF THE HUMAN VITAMIN D RECEPTOR LIGAND BINDING DOMAIN COMPLEXED WITH 1ALPHA,25-DIHYDROXY-2ALPHA-[2-(1H-TETRAZOLE-1-YL)ETHYL]VITAMIN D3 |
| 4J5W | D: | CRYSTAL STRUCTURE OF THE APO-PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX |
| 4J5X | C:; D: | CRYSTAL STRUCTURE OF THE SR12813-BOUND PXR/RXRALPHA LBD HETEROTETRAMER COMPLEX |
)
)